HD Clinical Trials

Prilenia Gives Huntington’s Disease Community HOPE

Author Therese Crutcher-Marin, HD Advocate

To the Huntington’s Disease community around the world; Do not lose HOPE. 

A couple of weeks ago, I had the pleasure to talk with Henk Schuring Chief Regulatory & Commercialization Officer about Prilenia; a clinical stage biotech company, led by Michael Hayden, MD, PhD., together with a highly experienced team with a track record of success.  Michael is a world-renowned scientist in Huntington Disease research.

Henk found my Huntington’s disease (HD) Advocacy & Author website and emailed me.

It’s a very exciting time since Prilenia is in Phase 3 of a clinical trial on the drug, Pridopidine, an oral drug currently in development for the treatment of Huntington’s disease and ALS. It is administered in a small easy-to-swallow capsule twice a day.

Prilenia participated in 2021 HDSA Convention. They were in the Exhibit Hall last June.


Clinical trials on pridopidine are being conducted in two (2) locations in California.  They are: 

We Can Never Lose HOPE…

Previous Post Next Post

You Might Also Like

No Comments

Leave a Reply